Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 23, 2020, titled "Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris Nasal Spray across numerous markets throughout Europe".